Syrris Celebrates its Most Successful Year to Date
News Feb 26, 2014
Syrris continues to lead the way with its batch reactor products and flow chemistry systems, increasing profits by over 50 % year-on-year.
This includes the top 20 pharmaceutical companies, leading universities and government institutes, plus companies working in fields such as food, flavor and fragrance, petrochemicals, nanoparticles and fine chemical synthesis.
Highlights of 2013 included a global series of workshops - enabling chemists to discover the advantages of flow and automated process chemistry - and the launch of an exclusive Customer Club, offering members easy access to a wide variety of select benefits and additional information.
Syrris also committed to a three-year, multi-million pound research and development program, part funded by European Union and Technology Strategy Board grants which were awarded in recognition of the Company’s ability to develop innovative, user-friendly and commercially successful products for chemists and chemical engineers.
The program will allow existing award-winning products, including Asia and Atlas reactors, to be further enhanced, and novel batch and flow chemistry products to be developed.
CEO Mike Hawes commented: “This is a really exciting time in Syrris’ history. Our most successful year ever has established Syrris as the market leader in flow chemistry products. The launch of our research and development program will deliver further world-class products offering the greatest control and ultimate ease of use to our customers, enabling a broader array of chemistry on a wider scale than ever before.”
“Lymphoma Micro-reactor” Targets Chemo-Resistant LymphomaNews
Researchers have developed a “lymphoma micro-reactor” device that exposes human lymphomas to fluid flow similar to that in the lymphatics and parts of the lymph node.READ MORE
Artificial Leaf Acts as a Mini Medicine FactoryNews
Using sunlight for sustainable and cheap production of, for example, medicines. The 'mini-factory' in the form of a leaf that was presented in 2016 showed that it is possible. Now researchers have come with an improved version: their 'mini-factory' is now able to keep production at the same level, irrespective of the variation in sunlight due to cloudiness or time of the day.READ MORE
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Comments | 0 ADD COMMENT
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018